Who the standard covers
The DOH Standard on Human Subject Research applies to "any type of facility or organization seeking to undertake research involving human subjects in the Emirate of Abu Dhabi", naming healthcare providers, healthcare professionals, educational institutions and pharmaceutical firms (section 2.1) (Department of Health Abu Dhabi, 2020). It covers clinical trials of investigational medicinal products, medical device trials, research with vulnerable people and other research with human participants. It excludes gene therapy and Phase I trials, animal-only research and umbilical cord blood biobanking, which have their own rules (Department of Health Abu Dhabi, 2020).
The definitions are broad. Research is a systematic investigation designed to develop or contribute to generalisable knowledge, and a human subject is an individual about whom an investigator obtains data through intervention or interaction, or identifiable private information (Department of Health Abu Dhabi, 2020). Interview, survey and records-based studies in health settings can therefore fall within it, not only drug trials.
Approval routes in practice
Every study needs REC approval before contact with participants (section 5.1.1). Universities in Abu Dhabi run their own committees: New York University Abu Dhabi, for example, states that its REC follows DoH policy and the DoH REC standard operating procedures for Abu Dhabi-based biomedical research and research involving human tissue (New York University Abu Dhabi, n.d.). UAE University in Al Ain requires approval from its Human Research Ethics Committee for any project involving human participants or human-derived material (United Arab Emirates University, 2025).
Studies classed as critical then go to the Abu Dhabi Health Research and Technology Committee. The list includes multi-centre studies, clinical trials, pharmaceutical-sponsored research, significant-risk studies, research on genetic material and genomics, and processing of medical data outside the UAE (section 4.3.1) (Department of Health Abu Dhabi, 2020). Build this second review into your plan; it is the step doctoral timelines most often underestimate.
Consent, data and storage
Section 6.6 is the part most likely to change a doctoral data plan. It asks for identifying information to be removed as soon as possible, consent forms kept for at least three years after the project ends, raw data archived securely within the emirate, and it prohibits cloud storage solutions (Department of Health Abu Dhabi, 2020). That rules out many default habits, such as syncing interview recordings to a personal cloud drive or analysing identifiable data in an overseas web tool.
Health data also sit outside the federal Personal Data Protection Law where they have their own legislation, so the DoH standard and federal health data law, not the PDPL alone, shape what you may do (United Arab Emirates, 2021). If your project spans emirates, check each regulator: in Dubai, the Dubai Health Authority's Clinical Trials Policy requires approval through its Medical Education and Research Department and the Dubai Scientific Research Ethics Committee, and GCP training refreshed at least every three years (Dubai Health Authority, 2023).
